Everolimus induces Met inactivation by disrupting the FKBP12/Met complex

Lucia Raimondo, Valentina D'Amato, Alberto Servetto, Roberta Rosa, Roberta Marciano, Luigi Formisano, Concetta di Mauro, Roberta Clara Orsini, Priscilla Cascetta, Paola Ciciola, Ana Paula de Maio, Maria Flavia di Renzo, Sandro Cosconati, Agostino Bruno, Antonio Randazzo, Filomena Napolitano, Nunzia Montuori, Bianca Maria Veneziani, Sabino de Placido, Roberto Bianco

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment strategy for several cancer types. Rapamycin derivatives such as everolimus are allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin FKBP12, a prolyl isomerase with different cellular functions. Although mTOR inhibitors have significantly improved survival of different cancer patients, resistance and lack of predictive factors of response remain unsolved issues. To elucidate the mechanisms of resistance to everolimus, we evaluated Met activation in everolimus-sensitive/resistant human cancer cells, in vitro and in vivo. Biochemical and computational analyses were performed. Everolimus-resistant cells were xenografted into mice (10/group) and studied for their response to everolimus and Met inhibitors. The statistical significance of the in vitro results was evaluated by Student's t test. Everolimus reduced Met phosphorylation in everolimus-sensitive cells. This event was mediated by the formation of a Met-FKBP12 complex, which in turn is disrupted by everolimus. Aberrant Met activation in everolimus-resistant cells and overexpression of wild-type/mutant Met caused everolimus resistance. Pharmacological inhibition and RNA silencing of Met are effective in condition of everolimus resistance (P<0.01). In mice xenografted with everolimus-resistant cells, the combination of everolimus with the Met inhibitor PHA665752 reduced tumor growth and induced a statistically significant survival advantage (combination vs control P=0.0005). FKBP12 binding is required for full Met activation and everolimus can inhibit Met. Persistent Met activation might sustain everolimus resistance. These results identify a novel everolimus mechanism of action and suggest the development of clinical strategies based on Met inhibitors in everolimus-resistant cancers.

Original languageEnglish
Pages (from-to)40073-40084
Number of pages12
JournalOncotarget
Volume7
Issue number26
Publication statusPublished - 2016

Fingerprint

Tacrolimus Binding Protein 1A
Sirolimus
Everolimus
Neoplasms
Immunophilins
Peptidylprolyl Isomerase

Keywords

  • Everolimus
  • Everolimus resistance
  • FKBP12
  • Met

ASJC Scopus subject areas

  • Oncology

Cite this

Raimondo, L., D'Amato, V., Servetto, A., Rosa, R., Marciano, R., Formisano, L., ... Bianco, R. (2016). Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. Oncotarget, 7(26), 40073-40084.

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. / Raimondo, Lucia; D'Amato, Valentina; Servetto, Alberto; Rosa, Roberta; Marciano, Roberta; Formisano, Luigi; di Mauro, Concetta; Orsini, Roberta Clara; Cascetta, Priscilla; Ciciola, Paola; de Maio, Ana Paula; di Renzo, Maria Flavia; Cosconati, Sandro; Bruno, Agostino; Randazzo, Antonio; Napolitano, Filomena; Montuori, Nunzia; Veneziani, Bianca Maria; de Placido, Sabino; Bianco, Roberto.

In: Oncotarget, Vol. 7, No. 26, 2016, p. 40073-40084.

Research output: Contribution to journalArticle

Raimondo, L, D'Amato, V, Servetto, A, Rosa, R, Marciano, R, Formisano, L, di Mauro, C, Orsini, RC, Cascetta, P, Ciciola, P, de Maio, AP, di Renzo, MF, Cosconati, S, Bruno, A, Randazzo, A, Napolitano, F, Montuori, N, Veneziani, BM, de Placido, S & Bianco, R 2016, 'Everolimus induces Met inactivation by disrupting the FKBP12/Met complex', Oncotarget, vol. 7, no. 26, pp. 40073-40084.
Raimondo L, D'Amato V, Servetto A, Rosa R, Marciano R, Formisano L et al. Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. Oncotarget. 2016;7(26):40073-40084.
Raimondo, Lucia ; D'Amato, Valentina ; Servetto, Alberto ; Rosa, Roberta ; Marciano, Roberta ; Formisano, Luigi ; di Mauro, Concetta ; Orsini, Roberta Clara ; Cascetta, Priscilla ; Ciciola, Paola ; de Maio, Ana Paula ; di Renzo, Maria Flavia ; Cosconati, Sandro ; Bruno, Agostino ; Randazzo, Antonio ; Napolitano, Filomena ; Montuori, Nunzia ; Veneziani, Bianca Maria ; de Placido, Sabino ; Bianco, Roberto. / Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. In: Oncotarget. 2016 ; Vol. 7, No. 26. pp. 40073-40084.
@article{b7b051b134764407a816ca16912f02c8,
title = "Everolimus induces Met inactivation by disrupting the FKBP12/Met complex",
abstract = "Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment strategy for several cancer types. Rapamycin derivatives such as everolimus are allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin FKBP12, a prolyl isomerase with different cellular functions. Although mTOR inhibitors have significantly improved survival of different cancer patients, resistance and lack of predictive factors of response remain unsolved issues. To elucidate the mechanisms of resistance to everolimus, we evaluated Met activation in everolimus-sensitive/resistant human cancer cells, in vitro and in vivo. Biochemical and computational analyses were performed. Everolimus-resistant cells were xenografted into mice (10/group) and studied for their response to everolimus and Met inhibitors. The statistical significance of the in vitro results was evaluated by Student's t test. Everolimus reduced Met phosphorylation in everolimus-sensitive cells. This event was mediated by the formation of a Met-FKBP12 complex, which in turn is disrupted by everolimus. Aberrant Met activation in everolimus-resistant cells and overexpression of wild-type/mutant Met caused everolimus resistance. Pharmacological inhibition and RNA silencing of Met are effective in condition of everolimus resistance (P<0.01). In mice xenografted with everolimus-resistant cells, the combination of everolimus with the Met inhibitor PHA665752 reduced tumor growth and induced a statistically significant survival advantage (combination vs control P=0.0005). FKBP12 binding is required for full Met activation and everolimus can inhibit Met. Persistent Met activation might sustain everolimus resistance. These results identify a novel everolimus mechanism of action and suggest the development of clinical strategies based on Met inhibitors in everolimus-resistant cancers.",
keywords = "Everolimus, Everolimus resistance, FKBP12, Met",
author = "Lucia Raimondo and Valentina D'Amato and Alberto Servetto and Roberta Rosa and Roberta Marciano and Luigi Formisano and {di Mauro}, Concetta and Orsini, {Roberta Clara} and Priscilla Cascetta and Paola Ciciola and {de Maio}, {Ana Paula} and {di Renzo}, {Maria Flavia} and Sandro Cosconati and Agostino Bruno and Antonio Randazzo and Filomena Napolitano and Nunzia Montuori and Veneziani, {Bianca Maria} and {de Placido}, Sabino and Roberto Bianco",
year = "2016",
language = "English",
volume = "7",
pages = "40073--40084",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "26",

}

TY - JOUR

T1 - Everolimus induces Met inactivation by disrupting the FKBP12/Met complex

AU - Raimondo, Lucia

AU - D'Amato, Valentina

AU - Servetto, Alberto

AU - Rosa, Roberta

AU - Marciano, Roberta

AU - Formisano, Luigi

AU - di Mauro, Concetta

AU - Orsini, Roberta Clara

AU - Cascetta, Priscilla

AU - Ciciola, Paola

AU - de Maio, Ana Paula

AU - di Renzo, Maria Flavia

AU - Cosconati, Sandro

AU - Bruno, Agostino

AU - Randazzo, Antonio

AU - Napolitano, Filomena

AU - Montuori, Nunzia

AU - Veneziani, Bianca Maria

AU - de Placido, Sabino

AU - Bianco, Roberto

PY - 2016

Y1 - 2016

N2 - Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment strategy for several cancer types. Rapamycin derivatives such as everolimus are allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin FKBP12, a prolyl isomerase with different cellular functions. Although mTOR inhibitors have significantly improved survival of different cancer patients, resistance and lack of predictive factors of response remain unsolved issues. To elucidate the mechanisms of resistance to everolimus, we evaluated Met activation in everolimus-sensitive/resistant human cancer cells, in vitro and in vivo. Biochemical and computational analyses were performed. Everolimus-resistant cells were xenografted into mice (10/group) and studied for their response to everolimus and Met inhibitors. The statistical significance of the in vitro results was evaluated by Student's t test. Everolimus reduced Met phosphorylation in everolimus-sensitive cells. This event was mediated by the formation of a Met-FKBP12 complex, which in turn is disrupted by everolimus. Aberrant Met activation in everolimus-resistant cells and overexpression of wild-type/mutant Met caused everolimus resistance. Pharmacological inhibition and RNA silencing of Met are effective in condition of everolimus resistance (P<0.01). In mice xenografted with everolimus-resistant cells, the combination of everolimus with the Met inhibitor PHA665752 reduced tumor growth and induced a statistically significant survival advantage (combination vs control P=0.0005). FKBP12 binding is required for full Met activation and everolimus can inhibit Met. Persistent Met activation might sustain everolimus resistance. These results identify a novel everolimus mechanism of action and suggest the development of clinical strategies based on Met inhibitors in everolimus-resistant cancers.

AB - Inhibition of the mechanistic target of rapamycin (mTOR) is a promising treatment strategy for several cancer types. Rapamycin derivatives such as everolimus are allosteric mTOR inhibitors acting through interaction with the intracellular immunophilin FKBP12, a prolyl isomerase with different cellular functions. Although mTOR inhibitors have significantly improved survival of different cancer patients, resistance and lack of predictive factors of response remain unsolved issues. To elucidate the mechanisms of resistance to everolimus, we evaluated Met activation in everolimus-sensitive/resistant human cancer cells, in vitro and in vivo. Biochemical and computational analyses were performed. Everolimus-resistant cells were xenografted into mice (10/group) and studied for their response to everolimus and Met inhibitors. The statistical significance of the in vitro results was evaluated by Student's t test. Everolimus reduced Met phosphorylation in everolimus-sensitive cells. This event was mediated by the formation of a Met-FKBP12 complex, which in turn is disrupted by everolimus. Aberrant Met activation in everolimus-resistant cells and overexpression of wild-type/mutant Met caused everolimus resistance. Pharmacological inhibition and RNA silencing of Met are effective in condition of everolimus resistance (P<0.01). In mice xenografted with everolimus-resistant cells, the combination of everolimus with the Met inhibitor PHA665752 reduced tumor growth and induced a statistically significant survival advantage (combination vs control P=0.0005). FKBP12 binding is required for full Met activation and everolimus can inhibit Met. Persistent Met activation might sustain everolimus resistance. These results identify a novel everolimus mechanism of action and suggest the development of clinical strategies based on Met inhibitors in everolimus-resistant cancers.

KW - Everolimus

KW - Everolimus resistance

KW - FKBP12

KW - Met

UR - http://www.scopus.com/inward/record.url?scp=84982893605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982893605&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 40073

EP - 40084

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -